Dennis Mulroy Sells 2,515 Shares of AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CFO Dennis Mulroy sold 2,515 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total transaction of $112,445.65. Following the sale, the chief financial officer directly owned 21,852 shares in the company, valued at $977,002.92. This trade represents a 10.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Dennis Mulroy also recently made the following trade(s):

• On Wednesday, January 7th, Dennis Mulroy sold 1,908 shares of AnaptysBio stock. The stock was sold at an average price of $45.11, for a total value of $86,069.88.
• On Monday, January 5th, Dennis Mulroy sold 3,363 shares of AnaptysBio stock. The shares were sold at an average price of $43.26, for a total value of $145,483.38.
• On Monday, December 22nd, Dennis Mulroy sold 10,000 shares of AnaptysBio stock. The shares were sold at an average price of $50.00, for a total value of $500,000.00.
• On Tuesday, December 16th, Dennis Mulroy sold 15,725 shares of AnaptysBio stock. The stock was sold at an average price of $44.85, for a total value of $705,266.25.

AnaptysBio Stock Performance

Shares of ANAB opened at $44.67 on Friday. The firm has a market cap of $1.24 billion, a PE ratio of -15.84 and a beta of 0.32. AnaptysBio, Inc. has a 52-week low of $12.21 and a 52-week high of $52.47. The business’s 50 day moving average price is $42.62 and its two-hundred day moving average price is $31.51.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The company had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. Research analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its board has initiated a share buyback program on Friday, November 21st that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Hedge Funds Weigh In On AnaptysBio

Several large investors have recently bought and sold shares of the stock. Larson Financial Group LLC grew its stake in shares of AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 473 shares in the last quarter. Rhumbline Advisers boosted its holdings in AnaptysBio by 2.7% during the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock worth $574,000 after purchasing an additional 826 shares during the last quarter. Bessemer Group Inc. grew its position in AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares in the last quarter. Corton Capital Inc. increased its stake in AnaptysBio by 12.2% in the 2nd quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock valued at $266,000 after buying an additional 1,305 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,377 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Wall Street Zen upgraded AnaptysBio from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. HC Wainwright cut their target price on AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Monday, November 24th. Wells Fargo & Company lifted their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. UBS Group initiated coverage on shares of AnaptysBio in a report on Wednesday. They set a “buy” rating and a $70.00 price objective on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $50.00 price objective on shares of AnaptysBio in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $60.40.

AnaptysBio News Summary

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded ANAB to a “strong‑buy” and raised its price target to $70, increasing visible upside and likely attracting retail and institutional flows. UBS upgrade / coverage note
• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro’s anticipatory‑breach claim in its Delaware Chancery Court dispute with GSK/Tesaro over Jemperli royalties; a favorable court outcome would lower potential royalty liabilities and legal uncertainty around future cash flows. Reuters: partial dismissal filing
• Positive Sentiment: Company has an active $100M buyback authorization (announced November), which supports shares by reducing float and signals board confidence in valuation.
• Neutral Sentiment: Several institutional investors have recently increased positions substantially (Assenagon, Woodline, 683 Capital, Arrowstreet), which can support liquidity but may not move price immediately.
• Negative Sentiment: Significant insider selling disclosed this week: CEO Daniel Faga sold ~9,202 shares (~$662k) and CFO Dennis Mulroy sold 1,908 shares (and has sold other blocks recently); additional insider dispositions by other executives were also filed — these sales can create near‑term selling pressure or raise questions about insider timing despite large remaining holdings. CEO sale article CFO Form 4
• Negative Sentiment: Clustered insider sales (multiple executives and directors) increase the visible supply and may blunt momentum from upgrades or legal progress until filings show stabilization. SEC Form 4 filings (insider sales)

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.